The aim of this study is to report outcomes and prognostic factors for early stage non-small cell lung cancer treated with patient-adapted Cyberknife stereotactic body radiotherapy. A retrospective analysis of 150 patients with T1-2N0 non-small cell lung cancer treated with stereotactic body radiotherapy was conducted. An algorithm based on tumor and patient's characteristics was used to orient patients towards soft tissue (Xsight Lung), fiducials or adjacent bone (Xsight Spine) tracking. Median biological effective dose without correction for tissue inhomogeneities was 180 Gy 10 for peripheral tumors and 113 Gy 10 for central tumors. Median follow-up was 22 months. Actuarial 2 years local control, overall survival and disease-specific survival were respectively 96%, 87% and 95%. Every 1 cm increase in tumor diameter was associated with a relative risk for regional or distant relapse of 2 (95%CI 5 1.2-3.6, p 5 0.009). With doses 132 Gy 10 and 132 Gy 10 , local control was 98% vs. 82% (p 5 0.07), disease-specific survival 97% vs. 78% (p 5 0.02) and overall survival 93% vs. 76% (p 5 0.01), respectively. Better disease-specific survival and a trend for better overall survival was observed for peripheral vs. central tumors (96% vs. 79%, p 5 0.05 and 92% vs. 74%, p 5 0.08, respectively). A higher Charlson comordibity score (4) predicted lower overall survival (79% vs. 98%, p 5 0.01). Toxicities included 3 patients with idiopathic pulmonary fibrosis who developed grade 5 pneumonitis and 2 patients with grade 3 pneumonitis.
Introduction
Non-small cell lung cancer (NSCLC) remains the first cause of mortality related to cancer worldwide (1) . Anatomic surgical resection (lobectomy or pneumonectomy) remains the standard treatment for stage 1 NSCLC (T1-T2N0M0) with Technology in Cancer Research & Treatment 2014 June 30. Epub ahead of print 2-year overall survival (OS) approaching 70% (2) . However, due to their advanced age at diagnosis and multiple comorbidities, a significant proportion of lung cancer patients are not surgical candidates. After the initial multicentric RTOG 0236 study (3) demonstrated LC as high as 90.6% at 3 years, stereotactic body radiotherapy (SBRT) (also referred to as stereotactic ablative radiotherapy in recent literature) became a standard option for inoperable patients with early stage NSCLC. Several subsequent studies (4-8) have confirmed excellent LC between 85% and 100% for peripheral tumors, with minimal toxicities. More recently, comparison studies have found SBRT outcomes to be similar to surgery (2, 9, 10) . Central tumors however remain at higher risk of severe grade 3-5 toxicities (47% vs. 16% for peripheral tumors) and therefore a protracted fractionation regimen is currently recommended for tumors in close proximity to the tracheo-bronchial tree (11) .
The CyberKnife ® (CK) robotic stereotactic radiosurgery system (Accuray Inc., Sunnyvale, CA, US) allows for near-real time target tracking. A patient-adapted treatment approach was adopted by our center using one of 3 methods: fiducial markers implantation, direct soft tissue tracking (Xsight Lung ® ) or use of an internal target volume (ITV) (based on 4D computed tomography scan motion) associated with the tracking of adjacent vertebrae (Xsight Spine ® ) (12) . In this study, we report LC, survival and toxicity results as well as prognostic factors in our cohort of early stage NSCLC treated with CK SBRT.
Material and Methods

Patients Characteristics
A retrospective analysis of all patients with early stage NSCLC treated with CK SBRT between July 2009 and December 2011 at our center was conducted. All patients had stage T1N0M0 or T2N0M0 tumors as per the American Joint Committee on Cancer 7th edition and were either ineligible for surgery or refused surgery. Metastatic and recurrent lesions were excluded. Investigations included: blood test including complete blood count and biochemistries, a thoracic computed tomography (CT) scan, bronchoscopy, 18-fluoro-2-deoxy-d-glucose positron emission tomographic (FDG-PET) scan, pulmonary functions tests and, when available, a histological confirmation of NSCLC. When pathological diagnosis could not be obtained, the decision to treat was taken by our multidisciplinary group after considering tumor progression on serial CT scans and FDG-PET uptake. Central tumors were defined as tumors within 2 cm of the tracheobronchial tree or adjacent to the mediastinum, as defined by RTOG 0618 (11) . Approval by our institutional ethics review board was obtained for this study.
Patient-adapted Cyberknife Target Tracking Method
Cyberknife version 8.5 and treatment planning system version 3.5 were used in this cohort. Selection of optimal CK tracking technique was made in a multidisciplinary meeting including radiation oncologists, radiologists and medical physicists. Choice of technique was based on patients' risk factors and tumor characteristics using the algorithm presented in Figure 1 .
Fiducial Markers Implantation:
In-treatment tumor tracking was achieved using 3 to 5 radiopaque (Figure 2A ) markers placed in or near the tumor. Transthoracic implantation under CT guidance was favored for most patients but endobronchial or endovascular placements were used in selected cases. Patients with forced expiratory volume in 1 sec (FEV1) of 1 L, large peri-tumoral emphysematous bullae or otherwise technically difficult implantation were excluded from fiducial implantation.
Direct Soft Tissue Tracking (Xsight Lung):
Tumor tracking was achieved using direct in-treatment soft tissue pattern detection ( Figure 2B ), obviating the need for fiducial markers implantation. Digitally reconstructed radiographs (DRRs) from the planning CT scan were matched with orthogonal X-rays taken at regular intervals in the treatment room. Patients' eligibility for this technique was verified with a pretreatment visualisation test. Larger and denser lesions were selected for this treatment method (13) .
Internal Target Volume (ITV) and Adjacent Vertebrae Tracking (Xsight Spine): In cases of inadequate Xsight
Lung tumor detection and unacceptable risks associated with fiducials implantations, an ITV based technique with adjacent vertebrae tracking was considered ( Figure 2C ). This technique was reserved for tumors in close proximity to adjacent vertebrae with limited motion confirmed by the 4D CT. To limit risks of geographic miss due to shift of the target in relationship to the spine, a 5 mm margin was added to an ITV and larger treatment cones were used.
CK Radiotherapy Treatment
All patients had a 3 mm slice thickness non-contrast 4D planning CT-scan in supine position. Immobilisation device included a custom foam cushion. Gross tumor volume (GTV) was determined using window level of 600 Hounsfield units (HU) and window width of 1600 HU. An additional planning tumor volume (PTV) margin of 3-5 mm was added to the GTV for fiducials or Xsight Lung cases or to the ITV for Xsight Spine cases. Dose calculation was achieved using Ray-Trace algorithm without corrections for tissue inhomogeneity. Dose was prescribed to a median isodose line of 75% (65-87%), covering at least 95% of the PTV. Lung constraints were as per the STARS Lung Trial and included: the percentage volume of lung (whole lung minus tumor) receiving more than 20 Gy being less than 20% (V20 Gy  20%), V10 Gy  30% and V5 Gy  50%. Dose constraints for all the other organs were as per RTOG 0236 and 0813.
Follow-up and Statistical Analysis
Tumor response was defined as per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 on followup CT-scans (14) . Follow-up CT-scans were obtained every 3 to 6 months in the first year and every 6 months thereafter. A complete response was defined as disappearance of tumor or replacement with radiation fibrosis. Any suspicious residual density after treatment was considered a partial response. Local failure was characterized by a recurrence within 2 cm of the tumor as well as recurrence within the involved lobe. Local relapse was defined as a suspicious mass progression at the site of the primary tumor at least 6 months after SBRT combined with a positive FDG-PET defined by a SUVmax  5 or a biopsy-proven confirmation. Regional failure was defined as recurrence with the hilum or mediastinum. Local recurrence was censored at the time of CT-scan progression. Toxicities were graded as per the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0.
Follow-up duration was defined as the time from the date of treatment completion to the date of last follow-up or death. Kaplan-Meier method was used for estimation of actuarial local control (LC), overall survival (OS) and disease-specific survival (DSS). Univariate and multivariate cox regression analysis were performed to determine predictors of disease recurrence and survival. With recent literature suggesting decreased outcomes with higher doses (15) , treatment regimens were separated a priori into high-dose (60 Gy in 3 fractions-180 Gy 10 and 60 Gy in 5 fractions-132 Gy 10 ) and intermediate-to-low dose (50 Gy in 4 fractions-113 Gy 10 ; 50 Gy in 5 fractions-100 Gy 10 and 40 Gy in 5 fractions-72 Gy 10 ). Dose (high vs. low-tointermediate), location (central vs. peripheral), stage, size, histology, CK technique as well as patients age, Charlson co-morbidity score and operability were entered in univariate analysis. Dose, tumor stage and tumor location were selected a priori for multivariate analysis after variance inflation factor (VIF) was used to ensure non-collinearity between variables.
Results
Patients Characteristics
Patients' characteristics are summarised in Table I . Five patients (3%) had pre-treatment radiological features of idiopathic pulmonary fibrosis (IPF). Histological diagnosis was 
Local Control and Survival
Median follow-up was 22 months. The actuarial 2 years LC, OS and DSS were respectively 96%, 87% and 95% (Figure 3 ). Local recurrences were biopsy proven for 2 patients (33%) and based on combined suspicious CT progression and SUVmax  5 on FDG-PET for 4 patients (67%). Causes of death included progressive lung cancer (6%), radiation pneumonitis (2%), cardiac events (3%), breast cancer (N 5 2) and head and neck cancer (N 5 1). Mortality rate at 90 days was 0.8% for all patients and 0% for operable patients. Local relapse was observed in 6 (5%) patients, regional relapse in 3 (2%) patients and distant relapse in 16 (12%) patients. Based on follow-up CT-scans, best response on last imaging was complete response, partial response and stable disease in 33 (25%), 48 (37%) and 23 (18%) patients, respectively.
Prognostic Factors
Local control was 98% for patients receiving a biologically effective dose (BED) 132 Gy 10 and 82% for patients receiving 113 Gy 10 (p 5 0.07). There was no statistically significant difference for LC between peripheral vs. central tumors (96% vs. 89%%, p 5 0.2) and between T1a/b vs. T2 tumors (96% vs. 91%, p 5 0.3) (Table II) . In this study, a dose 132 Gy 10 predicted a better DSS (97% vs. 78%, p 5 0.02) and OS (94% vs. 70%, p 5 0.01) ( Figure 3 ). Peripheral tumors had a better DSS compared to central tumors (96% vs. 79%, p 5 0.05) but difference in OS did not reach statistical significance (92% vs. 74% p 5 0.09). A trend towards a better DSS for T1a/b vs. T2 tumors (96% vs. 82%, p 5 0.07) was found but difference in OS between the 2 groups did not reach statistical significance (92% vs. 83% p 5 0.1) (Figure 4) . A Charlson co-moridbity score  4 predicted better OS (98% vs. 79%, p 5 0.01) (Table II) . Age, Charlson score, tumor histology, CK techniques and operability were not found to be predictive factors of LC or survival on univariate analysis. On logistic regression, tumor dimension was found to be predictive of regional/distant failure with a relative risk for failure of 2 with every 1 cm increase in tumor size (p 5 0.009, 95%CI 5 1.2-3.6). On multivariate analysis, there was a trend for improved OS with BED 132 Gy 10 (HR: 0.77 (95%CI 0.21-1.01; p 5 0.06). Neither tumor stage and location nor patients' operability were found predictive of failure (local, regional or distant) or OS. Assessment of collinearity between dose, stage and location revealed VIF of 1.6, 1.1 and 1.7 respectively.
Toxicities
Three of the 5 patients (60%) with radiologic features suggestive of IPF developed grade 5 pneumonitis at a median of 3.2 months (2.6-3.2) from treatment completion. Dosimetry based on Ray-Trace algorithm for these 3 patients is shown in Table III . Treatment plans were retrospectively calculated using Monte Carlo (MC) algorithm and compared to Ray-Trace algorithm. Differences between Ray-Trace and MC lung V5, V20 and mean lung dose were 0%, 11%, 0.1 Gy for the first patient, 0%, 0% and 0.1 Gy for the second patient and 2%, 0% and 1 Gy for the third patient (Table III) . Toxicities otherwise included 2 patients with grade 3 pneumonitis (both peripheral tumors), 8 patients (6%) with grade 2 costal tenderness and 5 patients (4%) with rib fractures. Among 66 patients treated using fiducial tracking, 9 patients (14%) had pneumothorax requiring chest tube placement. Of these, 7 (11%) occurred during combined biopsy plus fiducial implantation procedure. Mean dose (Gy) 11 8 5 Monte Carlo V5 Gy (%) 48 33 19 V20 Gy (%) 21 15 6 Mean dose (Gy) 11 8 4 Abbreviation: DLCO 5 Diffusing capacity for carbon monoxide.
Discussion
We report an excellent 2-years actuarial LC of 93% consistent with previous studies reporting LC rates between 85% and 98% at 2-3 years (3, 7, 8, 16, 17) . Likewise, our 2 years actuarial OS of 87% is higher than reported rates of 52-72% at 2-3 years. Alternative causes of death in this elderly population with multiple co-morbidities are thought to contribute to these lower OS numbers. The high OS of our cohort could be partly explained by the fact that 18% of patients were surgical candidates. Although most lung SBRT patients in the period covered by the study were treated using the CK (approximately 85%), a small proportion of patients with severe chronic obstructive lung disease (FEV1 1 L) who failed the Xsight Lung test and were not eligible to Xsight Spine were oriented towards alternative methods (RapidArc or Tomotherapy). This may also have contributed to the high OS observed in our cohort. There was no clear bias favoring CK in relationship to DSS as tumors size (a potent prognostic factor (13)) was the most important predictor of eligibility for Xsight Lung. Looking at DSS, our rate of 96% at 2 years is comparable to rates following surgery (17, 18) . On the other hand, whereas our cohort's 90-day mortality rate was 0.8%, a recent study reported rates of up to 6% with surgery (both extensive and limited resections) (19) .
Predictive Factors
Better outcomes were associated with BED  132 Gy 10 (trend towards better LC, better DSS and OS), smaller tumors (lower regional and distant failure and a trend towards improved DSS) and peripheral tumors (better DSS).
There is currently limited data available on optimal lung SBRT dose regimen balancing best outcomes with treatment risks. In a retrospective study, Onishi (22) found better LC and OS at 5 years for patients treated with BED  100 Gy 10 vs. BED  100 Gy 10 (LC of 92% vs. 57% and OS of 70.8 vs. 30.2%, respectively). In our study, better survival outcomes were found with BED  132 Gy 10 , corresponding to a regimen of 60 Gy in 3-5 fractions. Lower median dose to central tumors (median BED 113 Gy 10 , vs. 160 Gy 10 for peripheral) and T2 tumors (median of 132 Gy 10 vs. 180 Gy 10 for T1) could partly explain this finding. After Timmerman (11) . No difference in OS was found between central and peripheral tumors but LC outcomes were contradictory between studies. In general, LC was found to be 85% when BED was 100 Gy 10 . However, interpretation of this data is difficult considering patients, treatment planning and radiation delivery heterogeneities. In our study, risk-adapted doses to centrally located lesions resulted in minimal toxicities but could in part explain the lower DSS rate in this subgroup. The currently ongoing phase I RTOG 0813 trial aims at determining the maximal tolerated dose to centrally located tumors and has the potential to provide answers about optimal dose regimen for these lesions. Given the anatomical location of central tumors, a theoretical alternate explanation for the lower DSS could be that of a higher propensity of undetected regional micrometastases at the time of diagnosis.
Several studies have shown decreased outcomes with larger tumors with LC differences in the order of 20% between T1 and T2 tumors at 2-5 years (21, 22) . In a study by Baumann (8) , the estimated risk of all failures (local, regional and distant) was significantly increased for stage T2 tumors (41% vs. 18%). A prospective study by Hoyer (23) was the only study showing a difference in DSS between T2 and T1 tumors. In our series, larger tumor dimension was associated with higher rates of regional and distant metastasis and a worse DSS for T2 tumors, which is consistent with the current literature. The impact of larger tumors with regard to treatment dose is currently unclear. In our cohort, although median dose to T2 tumors was reduced, delivered dose was not tailored by tumor size but rather limited by dose constraints to organs at risk. The lower delivered dose could have contributed, at least partly, to the lower outcomes observed for larger tumors.
The small number of events (only 6 LR) along with the retrospective nature of the study constitute a limitation to our results. Borderline statistical significance reported for several predictive factors should be considered with caution and be regarded mainly as potential tracks to be further evaluated in future studies. In addition, LR was defined by mass progression on CT and SUVmax  5 on FDG-PET for 4 out of 6 LR. Definition of LR post SBRT remains challenging and emerging data attempts to identify high-risk features in order increase sensitivity and specificity of current imaging (24, 25) . Other metrics suggested to be predictive of recurrence such as sequential enlarging opacity, enlarging opacity after 12 months, bulging margins, loss of linear margin or air bronchogram loss were not evaluated in this study. Optimal identification of early LR remains to be defined and these high risks features need to be evaluated in further clinical studies.
Toxicities and Pulmonary Fibrosis
Although toxicities from lung SBRT are considered minimal, reported rates of radiation pneumonitis requiring clinical intervention range from 0% to 29% (7, (26) (27) (28) . A large Japanese survey (7) (33) . The surgical option is also associated with poor outcomes for this patient population. The American College of Chest Physicians and Society of Thoracic Surgeons consensus recently identified patients with IPF as high-risk patients with increased risk of complications following surgical resection with overall reduced survival and increased risk of mortality and pulmonary complication (34) (35) (36) .
In our study, 3 patients with IPF, 2 of which had limited DLCO (28% and 33%), developed grade 5 pneumonitis (2%). Whereas V20 Gy exceeded the RTOG 0236 acceptable limits for patients 1 and 2, the STARS V10 Gy and V20 Gy dose constraints were only exceeded by 1% for patient 1. For these 2 patients with large PTVs of 82 and 95 cm 3 , these were unavoidable compromises to ensure adequate tumor coverage. A reduction of the prescription dose (113 Gy 10 ) failed to achieve significant reduction of lung dose. Risks of severe toxicities with a curative approach were discussed with these 2 inoperable patients. They opted for a curative treatment with knowledge of the associated risks. For these patients, an increased lung volume irradiation remains a potential explanation to the fatal pneumonitis.
IPF is not an established contra-indication to lung SBRT and there is currently no predictive model to assess the probability of radiation pneumonitis. Until we develop a better understanding of the impact of IPF in lung SBRT, we recommend discussing risks of severe toxicities associated to treatment with these patients and application of more severe lung constraints.
Conclusion
Excellent LC and DSS are seen with CK lung SBRT. In general, toxicities are minimal but patients with IPF may be at greater risk of severe pulmonary toxicities. Better predictive models of radiation pneumonitis are needed and stricter dose constraints may be required for these patients. Small size, peripheral location and BED  132 Gy 10 were all associated with better outcomes.
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